Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors are ICIs that have been shown to significantly prolong the median progression-free survival (PFS) and overall survival (OS) in patients with NSCLC, including those with LUAD and LUSC [3]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.